Table 1.
Study population characteristics (N = 1086)
| Variable | N (%) | P value | ||
|---|---|---|---|---|
| Gender | Female Male |
684 (63.0) 402 (37.0) |
<0.001 | |
| Age | 18–24 years 25–65 years >66 years |
180 (16.6) 869 (80.0) 37 (3.4) |
<0.001 | |
| Marital status | Single Married |
539 (49.6) 547 (50.4) |
<0.001 | |
| Education level | School Diploma University Other |
74 (6.8) 888 (81.8) 83 (7.6) 41 (3.8) |
<0.001 | |
| Presence of chronic disease | No Yes |
856 (78.8) 230 (21.2) |
<0.001 | |
| Allergy | No allergy Seasonal allergy Food allergy Penicillin allergy |
805 (74.1) 232 (21.4) 23 (2.1) 25 (2.3) |
<0.001 | |
| Receive annual influenza vaccine | No Yes |
813 (74.9) 264 (24.3) |
<0.001 | |
| COVID19 vaccine | First dose only First and second dose |
787 (72.5) 299 (27.5) |
<0.001 | |
| Type of COVID19 vaccine | Pfizer Sinopharm AstraZeneca |
441 (40.6) 287 (26.4) 358 (33.0) |
<0.001 | |
|
History of COVID19 infection |
No Yes, before the vaccine. Yes, after the 1st dose Yes, after the 2nd dose |
838 (77.2) 205 (18.9) 38 (3.5) 5 (0.5) |
<0.001 |
|
| |
1st dose |
2nd dose |
P value |
|
| Having any side effect | No Yes |
110 (10.1) 976 (89.9) |
72 (24.0) 227 (75.9) |
0.101 |
| Require hospitalization | No Yes |
1041(95.9) 0 (0.0) |
297 (99.3) 2 (0.7) |
0.310 |
| Onset of symptoms | Immediately 1st day 1st week 2nd week 3rd week |
95 (8.7) 781(71.9) 68 (6.3) 10 (0.9) 4 (0.4) |
27 (9.7) 190 (63.5) 21 (7.0) 38 (12.7) 1 (0.3) |
0.358 |
| Medications used for symptoms relief after vaccination | Paracetamol (500–1000 mg) NSAIDS(ibuprofen, Diclofenac) Antihistamine Multivitamins Aspirin Esomeprazole Azithromycin Not receive any medication |
454(41.8) 26 (2.4) 3 (0.3) 4 (0.4) 9 (0.8) 2 (0.2) 3 (0.3) 117 (10.8) |
90 (8.3) 4 (0.4) 2 (0.2) 0 (0.0) 1 (0.1) 0 (0.0) 3 (0.3) 28 (2.6) |
0.251 |
NSAIDS: Non-steroidal anti- inflammatory drugs;N: population size.